No headlines found.
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
Globe Newswire (Fri, 3-Jan 9:01 AM ET)
Globe Newswire (Thu, 5-Dec 4:05 PM ET)
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
Globe Newswire (Thu, 14-Nov 4:15 PM ET)
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Globe Newswire (Wed, 13-Nov 12:22 PM ET)
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
Globe Newswire (Tue, 12-Nov 4:45 PM ET)
Globe Newswire (Thu, 24-Oct 9:15 AM ET)
Globe Newswire (Wed, 23-Oct 9:15 AM ET)
Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock trades on the NASDAQ stock market under the symbol CYCCP.
As of January 17, 2025, CYCCP stock price climbed to $8.50 with 23,168 million shares trading.
CYCCP has a market cap of $17.40 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CYCCP traded as high as $22.58 and as low as $5.17.
CYCCP has underperformed the market in the last year with a return of -56.3%, while SPY returned +28.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CYCCP shares. However, CYCCP has outperformed the market in the last 3 month and 2 week periods, returning +23.2% and +1.2%, while SPY returned +3.0% and +1.0%, respectively. This indicates CYCCP has been having a stronger performance recently.
CYCCP support price is $7.54 and resistance is $9.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CYCCP shares will trade within this expected range on the day.